Equities research analysts forecast that NewLink Genetics Corporation (NASDAQ:NLNK) will announce earnings per share (EPS) of ($0.80) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for NewLink Genetics Corporation’s earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.75). NewLink Genetics Corporation posted earnings of ($0.54) per share in the same quarter last year, which would suggest a negative year over year growth rate of 48.1%. The firm is expected to report its next earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that NewLink Genetics Corporation will report full-year earnings of ($2.79) per share for the current year, with EPS estimates ranging from ($3.05) to ($2.64). For the next financial year, analysts forecast that the firm will report earnings of ($2.44) per share, with EPS estimates ranging from ($3.29) to ($1.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover NewLink Genetics Corporation.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The company had revenue of $10.37 million for the quarter, compared to analyst estimates of $2.65 million.

Several brokerages recently issued reports on NLNK. Bank of America Corporation began coverage on shares of NewLink Genetics Corporation in a report on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. ValuEngine lowered shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a report on Monday, September 25th. Stifel Nicolaus lifted their price target on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 11th. Finally, Robert W. Baird raised shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $8.00 to $22.00 in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $25.83.

In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the business’s stock in a transaction that occurred on Friday, October 6th. The shares were acquired at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the transaction, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of NLNK. State of Wisconsin Investment Board acquired a new stake in NewLink Genetics Corporation during the 2nd quarter worth approximately $125,000. Trexquant Investment LP boosted its position in NewLink Genetics Corporation by 39.1% during the 2nd quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock worth $133,000 after buying an additional 5,097 shares during the period. Advisor Group Inc. boosted its position in NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after buying an additional 600 shares during the period. The Manufacturers Life Insurance Company boosted its position in NewLink Genetics Corporation by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in NewLink Genetics Corporation during the 2nd quarter worth approximately $165,000. Institutional investors and hedge funds own 54.77% of the company’s stock.

NewLink Genetics Corporation (NASDAQ NLNK) opened at 10.08 on Monday. The stock’s 50 day moving average is $11.21 and its 200-day moving average is $11.01. The firm’s market capitalization is $296.56 million. NewLink Genetics Corporation has a 12 month low of $5.90 and a 12 month high of $25.17.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/23/0-80-eps-expected-for-newlink-genetics-corporation-nlnk-this-quarter.html.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.